0000000000821699

AUTHOR

Luca Clivio

showing 4 related works from this author

Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study

2021

Abstract Purpose Triple-negative breast cancer (TNBC) represents a subtype of breast cancer which lacks the expression of oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2): TNBC accounts for approximately 20% of newly diagnosed breast cancers and is associated with younger age at diagnosis, greater recurrence risk and shorter survival time. Therapeutic options are very scarce. Aim of the present analysis is to provide further insights into the clinical activity of metronomic chemotherapy (mCHT), in a real-life setting. Methods We used data included in the VICTOR-6 study for the present analysis. VICTOR-6 is an Italian multicentre retrosp…

OncologyCancer Researchmedicine.medical_specialtyReceptor ErbB-2Breast NeoplasmsTriple Negative Breast NeoplasmsVinorelbineCapecitabine; Cyclophosphamide; Methotrexate; Metronomic chemotherapy; Triple-negative breast cancer; Vinorelbine; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cyclophosphamide; Female; Humans; Receptor ErbB-2; Retrospective Studies; Breast Neoplasms; Triple Negative Breast NeoplasmsCapecitabineErbB-2Breast cancerTriple-negative breast cancerRetrospective StudieInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProgression-free survivalCyclophosphamideTriple-negative breast cancerCapecitabineRetrospective StudiesAntineoplastic Combined Chemotherapy Protocolbusiness.industryMetronomic chemotherapyVinorelbinemedicine.diseaseClinical TrialMetronomic ChemotherapyMetastatic breast cancerRegimenMethotrexateOncologyFemalebusinessBreast NeoplasmHumanReceptormedicine.drug
researchProduct

Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patient…

2020

<b><i>Background:</i></b> Different studies suggest that fulvestrant 500 mg every 28 days (HD-FUL) could be an active treatment in HR+ advanced breast cancer (ABC) patients even treated with aromatase inhibitors in the adjuvant setting. The aim of this analysis is to describe the outcome of ABC patients treated with HD-FUL as first-line treatment in terms of median duration of treatment and the overall response rate in a real-world setting. <b><i>Methods:</i></b> For the purpose of the present analysis, we considered two data sets of HR+ ABC patients collected in Italy between 2012 and 2015 (EVA and GIM-13 AMBRA studies). <b><i>Res…

Oncologymedicine.medical_specialtymedicine.drug_classPopulationAnastrozoleNOInternal medicineFulvestrant · First-line setting · Hormone receptor positive Advanced breast cancermedicineAdjuvant therapyProgression-free survivaleducationFulvestrantFirst-Line settingeducation.field_of_studyHormone receptor positiveAromatase inhibitorFulvestrantEVAbusiness.industrytrialsCancerEndocrine TherapyGIM-13medicine.diseaseEndocrine Therapy HR+/HER2– Advanced Breast Cancer High-Dose Fulvestrant First-Line setting EVA GIM-13 AMBRA trialsAdvanced breast cancer; First-line setting; Fulvestrant; Hormone receptor positiveOncologyHR+/HER2–Advanced Breast CancerSurgeryAMBRAbusinessHigh-DoseTamoxifenResearch Articlemedicine.drug
researchProduct

Clinical evidence continuous medical education: a randomised educational trial of an open access e-learning program for transferring evidence-based i…

2008

Abstract Background In an effort to ensure that all physicians have access to valid and reliable evidence on drug effectiveness, the Italian Drug Agency sponsored a free-access e-learning system, based on Clinical Evidence, called ECCE. Doctors have access to an electronic version and related clinical vignettes. Correct answers to the interactive vignettes provide Continuing Medical Education credits. The aims of this trial are to establish whether the e-learning program (ECCE) increases physicians' basic knowledge about common clinical scenarios, and whether ECCE is superior to the passive diffusion of information through the printed version of Clinical Evidence. Design All Italian doctors…

Protocol (science)Medicine(all)Medical educationlcsh:R5-920Evidence-based practicebusiness.industryHealth PolicyComparabilityeducationHealth services researchPublic Health Environmental and Occupational HealthHealth InformaticsGeneral MedicineHealth informaticsHealth administrationStudy ProtocolContinuing medical educationMedicinebusinesslcsh:Medicine (General)Health policyImplementation Science
researchProduct

Metronomic chemotherapy (mCHT) in HER2-ve advanced breast cancer (ABC) patients (pts): What has changed over the time? Preliminary results of the VIC…

2017

e12552 Background: mCHT is the minimum biologically effective dose of a chemotherapeutic agent, given at regular dosing regimen with no prolonged drug free interval, that leads to anti-tumor activity. Old regimens included Cyclophosphamide-Methotrexate (CM), whereas in the last years new regimens, such as Vinorelbine (VRL) and Capecitabine (CAPE)-based have been developed. Aim of this observational retrospective ongoing study is to describe the use of mCHT in ABC pts across 5 years and the clinical characteristics of the pts together with efficacy of old (CM-like) vs new (VRL/CAPE-based) metronomic regimens in terms of response and disease control. Methods: We retrospectively identified fr…

0301 basic medicineOncologyDrugCancer Researchmedicine.medical_specialtybusiness.industryAdvanced breastmedia_common.quotation_subjectDosing regimenCancermedicine.diseaseEffective dose (pharmacology)Metronomic ChemotherapyFree intervalSurgery03 medical and health sciences030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicinemedicineMetronomic chemotherapy advanced breast cancerbusinessmedia_common
researchProduct